# OnCo record idea-reg-public-deescalation-trials-for-cost (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-reg-public-deescalation-trials-for-cost/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-reg-public-deescalation-trials-for-cost" ;
  schema:name "Publicly funded trials of lower and less frequent doses of expensive cancer drugs"@en ;
  schema:description "Abiraterone at a quarter dose with food matches full-dose exposure, and pembrolizumab and nivolumab can be given at longer intervals, but no manufacturer will fund trials that cut its own revenue. A public 'value trials' fund would run non-inferiority trials of lower doses and longer intervals for the highest-spend cancer drugs, with payers committing to adopt positive results."@en ;
  schema:url <https://onco.cc/ideas/idea-reg-public-deescalation-trials-for-cost/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1038/nrclinonc.2017.31> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/osimertinib/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-drug-pricing/>, <https://onco.cc/bottlenecks/b-dose-optimisation/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-prasad-nat-rev-clin-oncol/> .